Home Featured Page 69

Featured

Latest

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Magic Mushroom Formulations Update

Psychedelic Policy Reform & Legal Markets in 2023

Colorado Department of Revenue Natural Medicine Division Listening Sessions: Round 2

PT481 – Kanna: The History, Science, and Potential of an Emerging...

Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed...

Ensuring the Affordable Becomes Accessible – Lessons from Ketamine’s Antidepressant Development...

European Union Grants €6.5M for Multi-Site Psilocybin Study in Palliative Patients

PT480 – Psychedelics and Consent: Power Dynamics, Boundaries, and the Concept...

The Psychedelic News Feed: Dec 11 2023 – Jan 7, 2024

Psychedelics M&A and Partnerships in 2023

EDITOR PICKS

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.